Wed, August 11, 2010
Tue, August 10, 2010
Mon, August 9, 2010
Fri, August 6, 2010
Thu, August 5, 2010
Wed, August 4, 2010
Tue, August 3, 2010
Mon, August 2, 2010
Fri, July 30, 2010
Thu, July 29, 2010
Wed, July 28, 2010
Tue, July 27, 2010
Mon, July 26, 2010
Fri, July 23, 2010
Thu, July 22, 2010
Wed, July 21, 2010
Tue, July 20, 2010

Inhibitex to Host Conference Call to Report Second Quarter Financial Results on August 10, 2010


//health-fitness.news-articles.net/content/2010/ .. quarter-financial-results-on-august-10-2010.html
Published in Health and Fitness on by Market Wire   Print publication without navigation


ATLANTA--([ BUSINESS WIRE ])--Inhibitex, Inc. (NASDAQ: INHX) announced today that it will host a conference call on Tuesday, August 10, 2010 at 9:00 a.m. EDT to review the Companya�s second quarter financial results and provide an update on recent corporate developments. The Company will issue a press release regarding its financial results on the same day, prior to the conference call.

Webcast Information

To access the conference call, please dial (877) 407-9210 (domestic) or (201) 689-8049 (international). A replay of the call will be available from 11:00 a.m. Eastern Time on August 11th until September 10, 2010 at midnight. To access the replay, please dial (877) 660-6853 (domestic) or (201) 612-7415 (international) and reference the account # 286 and the conference id # 354732. A live audio webcast of the call and the archived webcast will be available in the News and Events section of the Inhibitex website at [ http://www.inhibitex.com ].

About Inhibitex

Inhibitex, Inc., headquartered in Alpharetta, Georgia, is a biopharmaceutical company focused on developing products to prevent and treat serious infectious diseases. The Companya�s pipeline includes FV-100, which is in Phase II clinical development for the treatment of shingles, and INX-189, a nucleotide polymerase inhibitor in development for the treatment of chronic hepatitis C infections. The Company also has additional HCV nucleotide polymerase inhibitors in preclinical development and has licensed the use of its proprietary MSCRAMM protein platform to Pfizer for the development of staphylococcal vaccines.

For additional information about the Company, please visit [ www.inhibitex.com ].


Publication Contributing Sources